Concourse Financial Group Securities, Inc. Chemomab Therapeutics Ltd. Transaction History
Concourse Financial Group Securities, Inc.
- $1.67 Billion
- Q4 2024
Number of Shares
0
Previous 0
NaN%
Holding current value
$0
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CMMB
# of Institutions
17Shares Held
4.16MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA1.74MShares$2.02 Million0.1% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L31.21MShares$1.41 Million0.51% of portfolio
-
Yelin Lapidot Holdings Management Ltd. Tel Aviv, L3744KShares$863,1870.23% of portfolio
-
Ikarian Capital, LLC Dallas, TX213KShares$247,1400.07% of portfolio
-
Morgan Stanley New York, NY104KShares$121,1030.0% of portfolio
About Chemomab Therapeutics Ltd.
- Ticker CMMB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 11,431,700
- Market Cap $13.3M
- Description
- Chemomab Therapeutics Ltd., a clinical-stage biotech company, discovers and develops therapeutics for the treatment of inflammation and fibrosis. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (...